Biomarkers /
SETD2
Overview
SET domain containing 2 (SETD2) is a gene that encodes a protein that is a member of a class of huntingtin interacting proteins. The protein functions as a histone methyltransferase specific for lysine-36 of histone H3. Missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and kidney cancer.
SETD2 is altered in 4.57% of all cancers with lung adenocarcinoma, colon adenocarcinoma, clear cell renal cell carcinoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in SETD2 are SETD2 Mutation (3.57%), SETD2-NF1 Fusion (0.37%), SETD2 Loss (0.08%), SETD2 X1572_splice (0.03%), and SETD2 Fusion (0.10%) [3].
Clinical Trials
Significance of SETD2 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.